Biologics Segment is Expected to be Fastest Growing During Forecast Period for MEA Region     

According to a new market research study on “MEA Diabetic Foot Ulcer Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type, Ulcer Type, and End User” is expected to reach US$ 244.73 million by 2028 from US$ 169.01 million in 2021. The market is estimated to grow at a CAGR of 5.4% from 2021 to 2028. The report provides trends prevailing in the MEA diabetic foot ulcer treatment market along with the drivers and restraints pertaining to the market growth.   Growing usage of 3D printing in wound care management and burgeoning research activities to introduce novel wound treatment products are the major factor driving the growth of the MEA diabetic foot ulcer treatment market. However, expensive advanced wound care treatments hinders the growth of MEA diabetic foot ulcer treatment market.    

In case of COVID-19, MEA is highly affected especially Turkey. The COVID-19 pandemic has become the most significant challenge in the region. This challenge would be particularly frightening for the region's fragile and conflict-torn states, such as Iraq (1,091,954), Sudan (33,648), Israel (838,767), and Yemen (6,414), because it will result in reduced imports due to global trade disruptions, which will exacerbate shortages of medical supplies and other goods, resulting in significant price rises. The Middle East countries have registered a growth in the number of COVID cases in the last few days. The MEA region include countries such as South Africa, the UAE, Turkey, and Saudi Arabia. These countries have also registered a significant number of positive coronavirus infection cases. These countries are developing in terms of the healthcare industry. The countries in these regions are highly dependent on imported medicinal products from developed countries. The lockdown has affected the supply chain of various companies in these regions. However, as the crisis continues and government relaxations on the import of the Diabetic Foot Ulcer Treatment products are expected to witness significant growth in the number of orders. However, as per the wound international report in South Africa, there is increased demand for wound care products since the outbreak of coronavirus in the country. The number of visits and types of wound treated are being delayed and preferred mode of consultation is through telephone calls and WhatsApp. This is likely to favor the growth of the Diabetic Foot Ulcer Treatment market in this region. Furthermore, as vaccination in MEA region progresses the burden on healthcare system will get released slowly which is expected to support the demand for diabetic foot ulcer treatment products.

The MEA diabetic foot ulcer treatment market is segmented based on the type, ulcer type, end user, and country. Based on type, the market has been segmented into the advanced wound care dressings, biologics, and therapy device. The advanced wound care dressings segment dominated the MEA diabetic foot ulcer treatment market in 2020 and biologics segment is expected to be fastest growing during forecast. Further, advanced wound care dressings is segmented into hydrogel dressings, collagen dressing, alginate dressings, foam dressings, hydrocolloid dressings, and others. Further, biologics is segmented into the skin grafts and growth factors. Similarly, therapy device is segmented into negative pressure wound therapy and ultrasound therapy. Based on ulcer type, the market has been segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The neuro-ischemic ulcers segment dominated the MEA diabetic foot ulcer treatment market in 2020 and same segment is expected to be fastest growing during forecast. Moreover, based on end user, the market has been segmented into the hospitals, ambulatory surgery centers, and home care. The hospital segment dominated the MEA diabetic foot ulcer treatment market in 2020 and same segment is expected to be fastest growing during forecast. Based on country, the market has been segmented into the UAE, Saudi Arabia, South Africa, and rest of MEA. 

3M; B. Braun Melsungen AG; Cardinal Health Inc; Coloplast Group; ConvaTec Group Plc; Medline Industries, Inc.; MiMedx; Mölnlycke Health Care AB.; Organogenesis Inc.; Smith & Nephew; and URGO    are among the leading companies in the MEA diabetic foot ulcer treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2018, Mölnlycke, has acquired German wound care products company, SastoMed GmbH. The deal adds new, award-winning products to Mölnlycke’s offer, enabling it to further help healthcare professionals and patients by accelerating the wound healing process and treating chronic wounds.                    

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com